FZD7 regulates BMSCs-mediated protection of CML cells
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1789 views | HTML 1765 views | ?
Na Liu1,*, Shaolei Zang1,*, Yan Liu1, Yingqiao Wang1, Wei Li1, Qiang Liu2, Min Ji1, Daoxin Ma1, Chunyan Ji1
1Department of Hematology Qilu Hospital, Shandong University, Ji’nan 250012, China
2Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, Ji’nan 250014, China
*These authors contributed equally to this work
Chunyan Ji, e-mail: [email protected]
Keywords: FZD7, CML, BMSCs, imatinib sensitivity, Wnt signaling pathway
Received: June 23, 2015 Accepted: December 09, 2015 Published: December 23, 2015
Inspite of effective treatment with imatinib (IM), chronic myeloid leukemia (CML) is still an incurable disease. Some patients became refractory because of IM resistance. Bone marrow mesenchymal stem cells (BMSCs) have been implicated a role in promoting CML cells’ resistance against IM treatment. The detailed molecular mechanisms, however, remain largely unknown. In this study, we found that BMSCs increased the expression of FZD7 and activated Wnt/β-catenin signaling pathway in CML cells. BMSCs from CML patients showed increased efficiency to accelerate CML cell proliferation, enhance the drug resistance of K562 cells and up-regulate the expression of FZD7. Antagonism of FZD7 expression by shRNA significantly suppressed proliferation and increased IM sensitivity of CML cells co-cultured with BMSCs cells. Our findings suggest that FZD7, involved in canonical Wnt signaling pathway, plays a critical role in mediating BMSCs-dependent protection of CML cells, and potentially provide a novel therapeutic target for CML.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.